Context: The challenge of tertiary alveolar grafting

Tertiary alveolar bone grafting (TABG) in adults born with a cleft lip and palate represents a highly demanding surgical challenge. Although this procedure is essential for long-term implant rehabilitation, it often takes place following the resorption of previous grafts, in an environment characterised by anatomical complexity and scarred soft tissues. For the practitioner, navigating this context of alveolar deficiency is hazardous, particularly as data regarding the complication patterns specific to these revision procedures remain fragmentary.

Objectives and hypotheses of the study

This clinical study set out to analyse the outcomes and complications of TABG in 13 adult patients over a six-month period. The surgical protocol was based on the use of autologous bone (harvested from the iliac crest or mandibular symphysis) combined with platelet-rich fibrin (PRF). The specific objective was to identify, through a structured analysis, recurrent trends and clinical patterns of complications.

The tested hypothesis suggests that complications are not random, but follow identifiable patterns where soft tissue compromise plays a central role, directly impacting graft stability and the successful placement of dental implants. By identifying these links, the study seeks to guide the practitioner towards a more integrated treatment planning than the mere evaluation of conventional outcomes.

Methodology: Analysis of a TABG case series

This clinical study, structured as a case series, evaluated the outcomes of tertiary alveolar bone grafting (TABG) in 13 adult patients presenting with a congenital alveolar cleft. The primary objective was to identify recurring patterns of complications during bone and implant reconstruction in these cases of previous graft resorption.

The experimental protocol and follow-up were based on the following specific parameters:

• Population and sample: 13 adult subjects with an alveolar deficiency. The mean initial volume of the cleft defect was 319.75 ± 187.11 mm³.
• Grafting materials: Autologous bone graft harvested from the iliac crest or the mandibular symphysis, combined with platelet-rich fibrin (PRF).
• Postoperative follow-up: Clinical and radiological observations and implant-related data were recorded over a six-month follow-up period.
• Analysis methods: The researchers used a structured analysis of clinical patterns (clinical pattern analysis) to correlate soft tissue complications with graft stability and implant failures (particularly the limits of primary stability).

Analysis of volumes and prevalence of complications

The study conducted on 13 adult patients presenting with a congenital alveolar cleft revealed a mean defect volume of 319.75 ± 187.11 mm³. The six-month postoperative follow-up shows an extremely high complication burden in this specific tertiary alveolar bone grafting (TABG) population.

The key finding of this case series is the universality of complications: 100% of the subjects experienced at least one postoperative adverse event. Mucosal fenestration was observed in all patients, presenting primarily as minor soft tissue exposures.

Clinical correlations and qualitative observations

Structural analysis of clinical patterns highlights a critical interdependence between soft tissue condition and the success of bone reconstruction. The authors report recurring trends directly linking soft tissue compromise to the challenges encountered during implantation.

• Soft tissue compromise: Central factor identified as a precursor to subsequent graft complications.
• Primary stability: Significant limitations were recorded in achieving satisfactory primary stability for dental implants.
• Graft instability: This phenomenon was observed concomitantly with mucosal exposures, compromising the final rehabilitation.

Radiological and clinical observations confirm that, although the use of autologous bone (iliac or symphyseal) combined with platelet-rich fibrin (PRF) is the strategy employed, the anatomical complexity of clefts in adults induces predictable resorption patterns and complications. The study emphasises that implant failure is often the endpoint of a cascade initiated by early tissue dehiscence.

Soft tissue management: the key to tertiary grafting

This study reveals a 100% incidence of complications among the 13 adult patients who underwent tertiary alveolar bone grafting (TABG). With a mean defect of 319.75 mm³, the use of autologous bone (mandibular or iliac) combined with PRF was not sufficient to prevent universal morbidity. The critical point identified is mucosal fenestration, observed in all subjects. This soft tissue compromise is not merely a superficial complication: it acts as the catalyst for the graft instability and primary implant stability failures observed during the six-month follow-up.

Clinically, these results suggest that in adults with a cleft, the tissue envelope is often too fibrous or deficient to support a standard large-volume bone reconstruction. The implant failures reported here are not isolated events but are part of a recurring pattern linking early tissue exposure and secondary volume loss. Unlike primary grafts, TABG encounters an already heavily scarred anatomical environment.

The limitations of this work stem from the small size of the case series (n=13) and a modest clinical follow-up. However, the strength of the study lies in demonstrating that conventional success criteria based on bone gain alone are insufficient. For the practitioner, these complication patterns require integrating aggressive soft tissue management into the initial planning, as bone grafting alone cannot compensate for mucosal coverage compromised by previous interventions.

Summary of the study

This case series, conducted on 13 adult patients, reveals that tertiary alveolar bone grafting (TABG) presents a 100% complication rate. Despite the addition of autologous bone and PRF to fill mean defects of 319.75 ± 187.11 mm³, mucosal fenestration was observed in all subjects, leading to graft instability and compromising the primary stability of the implants.

In practical terms, for the practitioner:

• Secure the mucosal seal: Soft tissue management is the critical aspect; as fenestration is almost systematic in adults, favour advanced flap techniques to reduce tension and protect the graft.
• Anticipate implant difficulties: Do not take the regenerated bone volume for granted; plan for adapted drilling protocols or extended loading periods given the high risk of primary instability.
• Include the risk of failure in the estimate: Clearly inform the patient that tertiary surgery in adult cleft patients presents a complex prognosis, where implant success directly depends on the survival of the peri-implant soft tissues.

Technical glossary of the study

Tertiary Alveolar Bone Grafting (TABG) : Tertiary alveolar bone grafting procedure performed in the adult patient to correct an alveolar deficiency secondary to the resorption of a previous graft.

Platelet-Rich Fibrin (PRF): Autologous platelet concentrate used in this study in combination with iliac or symphyseal bone to optimise the healing processes and graft integration.

Mucosal fenestration: Soft tissue complication characterised by graft exposure through the mucosa, universally observed in all subjects of this case series.

Primary implant stability : Initial mechanical stability of the dental implant at the time of placement, the achievement of which has been identified as a major clinical challenge following the TABG procedure.

Graft instability: Failure of fixation or integration of the bone graft (autologous), constituting one of the recurrent complication patterns analysed during the six-month follow-up.

Cleft defect volume: Three-dimensional measurement of the alveolar cleft volume (established at 319.75 ± 187.11 mm³ on average in this cohort), used to assess the extent of reconstruction required.

Information intended for healthcare professionals. This content may contain errors or truncated summaries. We recommend always checking against the original source article. Delynov disclaims all liability regarding the use of this information. This document is not intended for patients or the general public.